| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2a819eda0adf22936a52362eeebb9fb4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9de32f6289dcf304fcf935f042feceae |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-77
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-75
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-34 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-18 |
| filingDate |
2008-02-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d08a56eeb5805ee34a47d084b4661e2d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c5b5dfd5611ed6a1a1389892b1c01a4f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_89f5d0766d9cbd0b0e60ab9c5d265cd6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bdd25a154f8b7ef76ad4509c4e23ec7d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_710053dea91fa99e8a1a28f180eec385
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bbdbb53260ac688b311c33e814c89dbe |
| publicationDate |
2016-02-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
HU-E025225-T2 |
| titleOfInvention |
Prevention and treatment of synucleinopathic and amyloidogenic diseases |
| abstract |
The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful for prophylactic and therapeutic treatment of Parkinson's disease. |
| priorityDate |
2007-02-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |